WallStreetZenWallStreetZen

NASDAQ: BTAI
Bioxcel Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for BTAI

Based on 4 analysts offering 12 month price targets for Bioxcel Therapeutics Inc

Min Forecast
$4.00+129.89%
Avg Forecast
$49.25+2,730.46%
Max Forecast
$80.00+4,497.7%

Should I buy or sell BTAI stock?

Based on 4 analysts offering ratings for Bioxcel Therapeutics Inc.

Buy
Strong Buy
2 analysts 50%
Buy
1 analysts 25%
Hold
0 analysts 0%
Sell
1 analysts 25%
Strong Sell
0 analysts 0%
Although BTAI's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates BTAI as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their BTAI stock forecasts and price targets.

BTAI stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-19
lockedlocked$00.00+00.00%2025-01-30
lockedlocked$00.00+00.00%2025-01-07
lockedlocked$00.00+00.00%2025-01-06

1 of 1

Forecast return on equity

Is BTAI forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is BTAI forecast to generate an efficient return on assets?

Company
N/A
Industry
35.52%

BTAI earnings per share forecast

What is BTAI's earnings per share in the next 2 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$16.44
Avg 2 year Forecast
-$23.76

BTAI revenue forecast

What is BTAI's revenue in the next 1 years based on estimates from 1 analyst?

Avg 1 year Forecast
$3.5M+54.9%
BTAI's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BTAI revenue growth forecast

How is BTAI forecast to perform vs Biotechnology companies and vs the US market?

Company
281.77%
Industry
65.42%
Market
10.4%
BTAI's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BTAI's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BTAI vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BTAI$1.74$49.25+2,730.46%Buy
RLMD$0.29$1.00+244.83%Hold
ERNA$0.19N/AN/A
ATHA$0.24N/AN/A
HOOK$0.77$4.50+482.15%Buy
View Top Biotech Stocks

Bioxcel Therapeutics Stock Forecast FAQ

Is Bioxcel Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: BTAI) stock is to Buy BTAI stock.

Out of 4 analysts, 2 (50%) are recommending BTAI as a Strong Buy, 1 (25%) are recommending BTAI as a Buy, 0 (0%) are recommending BTAI as a Hold, 1 (25%) are recommending BTAI as a Sell, and 0 (0%) are recommending BTAI as a Strong Sell.

If you're new to stock investing, here's how to buy Bioxcel Therapeutics stock.

What is BTAI's earnings growth forecast for 2025-2026?

(NASDAQ: BTAI) Bioxcel Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.37%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.2%.

Bioxcel Therapeutics's earnings in 2025 is -$59,599,000.On average, 2 Wall Street analysts forecast BTAI's earnings for 2025 to be -$90,163,035, with the lowest BTAI earnings forecast at -$127,660,104, and the highest BTAI earnings forecast at -$52,665,965.

In 2026, BTAI is forecast to generate -$130,348,263 in earnings, with the lowest earnings forecast at -$130,348,263 and the highest earnings forecast at -$130,348,263.

What is BTAI's revenue growth forecast for 2025-2025?

(NASDAQ: BTAI) Bioxcel Therapeutics's forecast annual revenue growth rate of 281.77% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.4%.

Bioxcel Therapeutics's revenue in 2025 is $2,266,000.

In 2025, BTAI is forecast to generate $19,255,993 in revenue, with the lowest revenue forecast at $19,255,993 and the highest revenue forecast at $19,255,993.

What is BTAI's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: BTAI) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 35.52%.

What is BTAI's Price Target?

According to 4 Wall Street analysts that have issued a 1 year BTAI price target, the average BTAI price target is $49.25, with the highest BTAI stock price forecast at $80.00 and the lowest BTAI stock price forecast at $4.00.

On average, Wall Street analysts predict that Bioxcel Therapeutics's share price could reach $49.25 by Mar 19, 2026. The average Bioxcel Therapeutics stock price prediction forecasts a potential upside of 2,730.46% from the current BTAI share price of $1.74.

What is BTAI's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: BTAI) Bioxcel Therapeutics's current Earnings Per Share (EPS) is -$23.51. On average, analysts forecast that BTAI's EPS will be -$16.44 for 2025, with the lowest EPS forecast at -$23.27, and the highest EPS forecast at -$9.60. In 2026, BTAI's EPS is forecast to hit -$23.76 (min: -$23.76, max: -$23.76).

What is BTAI's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: BTAI) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.